baby, there is insufficient evidence for reliable conclusions about the effects on stillbirth or death after delivery (risk ratio (RR) 1.08, 95% confidence interval (CI) 0.69 to 1.71; four studies; 425 women). Babies whose mothers had been allocated to the interventionist group had more intraventricular haemorrhage (RR 1.82, 95% CI 1.06 to 3.14; one study; 262 women), more hyaline membrane disease (RR 2.30, 95% CI 1.39 to 3.81; two studies; 133 women), require more ventilation (RR 1.50, 95% CI 1.11 to 2.02; two studies; 300 women) and were more likely to have a lower gestation at birth in days (average mean difference (MD) -9.91, 95% ; four studies; 425 women), more likely to be admitted to neonatal intensive care (RR 1.35, 95% CI 1.16 to 1.58) and have a longer stay in the neonatal intensive care unit (average MD 11.14 days, 95% CI 1.57 to 20.72 days; two studies; 125 women) than those allocated an expectant policy. Nevertheless, babies allocated to the interventionist policy were less likely to be small-for-gestational age (RR 0.30, 95% CI 0.14 to 0.65; two studies; 125 women). Women who had been allocated to the interventionist group were more likely to have a caesarean section (RR 1.09, 95% CI 1.01 to 1.18; four studies; 425 women) than those allocated an expectant policy. There were no statistically significant differences between the two strategies for any other outcomes.
Authors' conclusions
This review suggests that an expectant approach to the management of women with severe early onset pre-eclampsia may be associated with decreased morbidity for the baby. However, this evidence is based on data from only four trials. Further large trials are needed to confirm or refute these findings and establish if this approach is safe for the mother.
P L A I N L A N G U A G E S U M M A R Y

Interventionist versus expectant care for severe pre-eclampsia before term
Women who develop pre-eclampsia (high blood pressure and protein in the urine) before 34 weeks of pregnancy (early onset) are at risk of severe complications, and even death. These involve the woman's liver, kidneys, clotting system and cause neurological disturbances such as headache, visual disturbances, and exaggerated tendon reflexes. If the placenta is involved, this can cause growth restriction or reduced amniotic fluid, placing the baby at risk. The only known cure for pre-eclampsia is delivery of the baby. Being born too early can in itself have problems for the baby, even with the administration of corticosteroids 24 to 48 hours beforehand to help mature the lungs. Some hospitals follow a policy of early delivery within 24 to 48 hours, interventionist management, whilst others prefer to delay delivery until it is no longer possible to safely stabilise the woman's condition, expectant management.
This review included four trials that randomly assigned women to a policy of interventionist management or expectant management when presenting with severe pre-eclampsia before 34 weeks of pregnancy. A total of 425 women were included in these four trials. Babies born to women allocated to an interventionist approach were more likely to experience adverse effects such as intraventricular haemorrhage and neonatal respiratory distress syndrome. They were also more likely to require admission to the neonatal intensive care unit and ventilation, have a longer stay in the neonatal unit and weigh less at birth than those babies born to women allocated to an expectant management approach. Women in the interventionist group were also more likely to require caesarean section for delivery. Delaying delivery may therefore be more beneficial for the baby. There are insufficient data, however, for reliable conclusions about the comparative effects on most outcomes for the mother and hence the maternal safety of an expectant approach.
This evidence is based on data from only four small trials. Further large trials with long-term follow-up of the children are needed to confirm or refute whether expectant care is better than early delivery for women who suffer from severe pre-eclampsia before 34 weeks of pregnancy.
B A C K G R O U N D
Pre-eclampsia is a multisystem disorder that is usually associated with raised blood pressure and proteinuria, but can also involve the woman's liver, kidneys, clotting system, or brain. If the placenta is involved this may lead to growth restriction or premature birth. Pre-eclampsia is a relatively common complication of pregnancy, and can occur at any time during the second half of pregnancy or in the first few weeks after delivery. Prediction models for adverse maternal outcome have been developed and validated in recent times (von Dadelszen 2011), but there is still a paucity of data to guide the clinician on the timing of delivery to ensure safety of both the mother and the baby in the long term. Pre-eclampsia is described in more detail in the generic protocol on interventions for treatment of pre-eclampsia and its consequences (Duley 2009 ).
Description of the condition
Hypertension in pregnancy is defined as a systolic blood pressure of 140 mmHg or more, and/or a diastolic pressure of 90 mmHg or more. To be diagnosed with pre-eclampsia the hypertension has to arise de novo after 20 weeks of pregnancy in combination with proteinuria defined as greater than 300 mg of total protein in a 24-hour urine collection (Davey 1988) . Recently, proteinuria has been assessed using a spot urine measuring the protein to creatinine ratio. A protein: creatinine ratio of 30 mg/mmol correlates with a 24-hour protein excretion of greater than 300 mg in 24 hours (Morris 2012) . This method of estimating the amount of protein being excreted has several advantages over the 24-hour urine collection and has been endorsed in a Royal College of Obstetricians and Gynaecologists (RCOG) Pre-eclampsia study group consensus statement (RCOG 2003) . However, pre-eclampsia is a multisystem disorder and the diagnosis of hypertension and proteinuria is considered to be too restrictive for clinical practice. Clinicians are all too aware that the disease can present in several ways and it is necessary to be vigilant when assessing women with symptoms and signs that are strongly associated with the disease. This has led to a widening of the definition for clinical purposes, to include the following: de novo hypertension after 20 weeks' gestation and new onset of one of the following: a) proteinuria as defined above; b) renal insufficiency (creatinine > 0.09 mmol/L, or oliguria; c) liver disease (raised transaminases and/or severe right upper quadrant or epigastric pain); d) neurological problems, convulsions (eclampsia), hyper-reflexia with clonus (involuntary muscular contractions), severe headaches, persistent visual disturbances (scotoma); e) haematological disturbances: thrombocytopenia (reduced numbers of platelets), disseminated intravascular coagulation, haemolysis; or f ) fetal growth restriction (Brown 2001) . There is no widely accepted definition of severe pre-eclampsia (Duley 2009). Nevertheless, the features described above in combination with the early onset of the disease between 24 and 34 weeks' gestation, would be considered by most clinicians to represent severe pre-eclampsia. We therefore did not further define nor categorise "severity".
Description of the intervention
Within clinical practice, some units advocate early delivery, which has been referred to as 'aggressive management' (Sibai 1984) , but in this review the term 'interventionist' is preferred. This means delivery by either induction of labour or caesarean section after corticosteroids have been given to improve fetal lung maturation, which in practice is after 24 to 48 hours (Crowley 1996) . Others prefer to give corticosteroids, stabilise the woman's condition and then, if possible, aim to delay delivery. This is usually known as 'expectant management' (Derham 1989) . The greatest dilemma in when to deliver is balancing the risks to mother and baby when the pregnancy is somewhere between 24 to 34 weeks. Early delivery resulting in a very premature baby could lead to more neonatal complications such as respiratory distress syndrome (difficulty in breathing and oxygenation), intraventricular haemorrhage (bleeding into the cavities of the brain) and necrotising enterocolitis (bleeding into the wall of the bowel due to a lack of oxygen). Conversely, delaying delivery in an attempt to allow fetal maturation could place the mother in jeopardy and at risk of multisystem organ failure as outlined above. It also prolongs the time that a fetus is in a potentially hostile in utero environment. This in turn will continue to adversely affect the growth of the fetus and may result in an intrauterine death, from severe hypoxia or an acute event such as an abruption. Although the precise cut offs for gestational age will vary with different settings, before 24 weeks the child has little chance of survival. After 34 weeks the prognosis improves with nearly 100 per cent survival. Between 24 and 34 weeks mortality decreases with increasing gestational age, but especially below 28 weeks there is also considerable risk of survival with severe disability. A structured review of observational studies found that expectant care for severe pre-eclampsia was associated with a prolongation of the pregnancy by between one and two weeks with better outcomes for babies and low risks for the mother. There were fewer neonatal deaths and complications of prematurity (Magee 2009).
Why it is important to do this review
This difficult clinical dilemma occurs relatively frequently in large units, and currently decisions are based mainly upon personal experience rather than good evidence. There is a great need for reliable data to help inform this decision-making. Other aspects of care for women with severe pre-eclampsia are dealt with in other reviews. These include drugs for lowering very high blood pressure (Duley 2006) , prophylactic anticonvulsants (Duley 2010) and plasma volume expansion (Duley 1999b). Prevention of pre-eclampsia is covered by reviews of calcium supplementation 
O B J E C T I V E S
To evaluate the comparative benefits and risks of a policy of early delivery by induction of labour or by caesarean section after suf-ficient time has elapsed to administer corticosteroids, and allow them to take effect; with a policy of delaying delivery (expectant care) for women with severe pre-eclampsia between 24 and 34 weeks.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All adequately randomised trials comparing interventionist (aggressive) with expectant care (delayed delivery) for women with severe early onset pre-eclampsia. Quasi-random designs, such as alternate numbers or allocation by the day of the week, were excluded.
Types of participants
Women with severe pre-eclampsia before or equal to 34 weeks' gestation. Severe pre-eclampsia was defined as high blood pressure, > 140/90 mmHg on two consecutive occasions four or more hours apart and proteinuria greater than 300 mg/24 hours. Alternatively as:
• severe hypertension (blood pressure at least 160 mmHg systolic, or 110 mmHg diastolic) alone; or hypertension as defined above plus one or more of the following criteria:
• severe proteinuria (usually at least 3 g (range 2 g to 5 g) protein in 24 hours, or 3+ on dipstick);
• reduced urinary volume (less than 500 mL in 24 hours), upper abdominal pain, pulmonary oedema;
• neurological disturbances (such as headache, visual disturbances, and exaggerated tendon reflexes);
• impaired liver function tests, high serum creatinine, low platelets;
• suspected intrauterine growth restriction or reduced liquor volume.
This latter set of criteria reflect the natural history of the disease and clinical practice when diagnosing severe pre-eclampsia.
Types of interventions
Any comparison of a policy of early elective delivery by induction of labour or by caesarean section (interventionist management) with a policy of delayed delivery (expectant management). If corticosteroids were used within the trial, they should have been used for both types of care. As the beneficial effects of a course of corticosteroids are so important, any study where corticosteroids were only administered to one group but not the other was excluded.
Types of outcome measures Primary outcomes
For the woman 5. weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts. Details of the search strategies for CENTRAL, MEDLINE and Embase, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the 'Specialized Register' section within the editorial information about the Cochrane Pregnancy and Childbirth Group. Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co-ordinator searches the register for each review using the topic list rather than keywords. For details of additional searching carried out in the previous version of the review, please see Appendix 1. We did not apply any language restrictions.
Data collection and analysis
For the methods used when assessing the trials identified in the previous version of this review, see Appendix 2. For this update we used the following methods when assessing the reports identified by the updated search. The two already included studies (Odendaal 1990; Sibai 1994) were also re-assessed using the following methods for 'Risk of bias' assessment.
Selection of studies
Two review authors (D Churchill (DC); L Jones (LJ)) independently assessed for inclusion all the potential studies identified as a result of the search strategy. We resolved any disagreement through discussion or, if required, we consulted a third author.
Data extraction and management
We designed a form to extract data. For eligible studies, two review authors (DC; LJ) independently extracted the data using the agreed form. We resolved discrepancies through discussion or, if required, we consulted a third author. We entered data into Review Manager software (RevMan 2012) and checked for accuracy. When information regarding any of the above was unclear, we contacted authors of the original reports to provide further details.
Assessment of risk of bias in included studies
Two review authors independently assessed the risk of bias for each study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). Disagreement was resolved by discussion or by involving a third author.
(1) Sequence generation (checking for possible selection bias)
We described for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. We assessed the method as:
• low risk of bias (any truly random process, e.g. random number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection bias)
We described for each included study the method used to conceal allocation to interventions prior to assignment and assessed whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or nonopaque envelopes, alternation; date of birth);
• unclear risk of bias. We described for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We considered that studies were at low risk of bias if they were blinded, or if we judged that the lack of blinding would be unlikely to affect results. We planned to assess blinding separately for different outcomes or classes of outcomes.
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel. We described for each included study the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received. We planned to assess blinding separately for different outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data)
We described for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported and the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported, or could be supplied by the trial authors, we planned to re-include missing data in the analyses which we undertook. We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; 'as treated' analysis done with substantial departure of intervention received from that assigned at randomisation);
(5) Selective reporting bias
We described for each included study how we investigated the possibility of selective outcome reporting bias and what we found. We assessed the methods as:
• low risk of bias (where it is clear that all of the study's prespecified outcomes and all expected outcomes of interest to the review have been reported);
• high risk of bias (where not all the study's pre-specified outcomes have been reported; one or more reported primary outcomes were not prespecified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported);
(6) Other sources of bias (checking for bias due to problems not covered by (1) to (5) above)
We described for each included study any important concerns we had about other possible sources of bias. We assessed whether each study was free of other problems that could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
We made explicit judgements about whether studies were at high risk of bias, according to the criteria given in the Cochrane Handbook (Higgins 2011). With reference to (1) to (6) above, we assessed the likely magnitude and direction of the bias and whether we considered it likely to impact on the findings. We planned to explore the impact of the level of bias through undertaking sensitivity analyses -see Sensitivity analysis.
Measures of treatment effect Dichotomous data
For dichotomous data, we presented results as summary risk ratios with 95% confidence intervals.
Continuous data
For continuous data, we used the mean difference if outcomes were measured in the same way between trials. We planned to use the standardised mean difference to combine trials that measured the same outcome, but used different methods, if required.
Unit of analysis issues
Cluster-randomised trials
If we identify cluster-randomised trials in future updates, we will include them in the analyses along with individually-randomised trials. We will adjust their sample sizes using the methods described in the Cochrane Handbook using an estimate of the intracluster correlation co-efficient (ICC) derived from the trial (if possible), from a similar trial or from a study of a similar population. If we use ICCs from other sources, we will report this and conduct sensitivity analyses to investigate the effect of variation in the ICC. If we identify both cluster-randomised trials and individually-randomised trials, we plan to synthesise the relevant information. We will consider it reasonable to combine the results from both if there is little heterogeneity between the study designs and the interaction between the effect of intervention and the choice of randomisation unit is considered to be unlikely. We will also acknowledge heterogeneity in the randomisation unit and perform a sensitivity analysis to investigate the effects of the randomisation unit.
Cross-over trials
Cross-over trials are not a valid study design for this review.
Dealing with missing data
For included studies, we noted levels of attrition. We explored the impact of including studies with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis. For all outcomes, we carried out analyses, as far as possible, on an intention-to-treat basis, i.e. we attempted to include all participants randomised to each group in the analyses, and all participants were analysed in the group to which they were allocated, regardless of whether or not they received the allocated intervention. The denominator for each outcome in each trial was the number randomised minus any participants whose outcomes were known to be missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using the T 2 , I² and Chi² statistics. We regarded heterogeneity as substantial if the T 2 is greater than zero and either the I 2 was greater than 30% or there was a low P value (less than 0.10) in the Chi² test for heterogeneity.
Assessment of reporting biases
In future updates, if there are 10 or more studies in the metaanalysis we will investigate reporting biases (such as publication bias) using funnel plots. We will assess funnel plot asymmetry visually. If asymmetry is suggested by a visual assessment, we will perform exploratory analyses to investigate it.
Data synthesis
We carried out statistical analysis using the Review Manager software (RevMan 2012). We used fixed-effect meta-analysis for combining data where it was reasonable to assume that studies were estimating the same underlying treatment effect: i.e. where trials were examining the same intervention, and the trials' populations and methods were judged sufficiently similar. If there was clinical heterogeneity sufficient to expect that the underlying treatment effects differed between trials, or if substantial statistical heterogeneity was detected, we used random-effects meta-analysis to produce an overall summary if an averaged treatment effect across trials was considered clinically meaningful. The random-effects summary was treated as the average of the range of possible treatment effects and we discussed the clinical implications of treatment effects differing between trials. If the average treatment effect was not clinically meaningful, we did not combine trials. If we used random-effects analyses, the results were presented as the average treatment effect with its 95% confidence interval, and the estimates of T 2 and I 2 .
Subgroup analysis and investigation of heterogeneity
In future updates, if we identify substantial heterogeneity, we will investigate it using subgroup analyses and sensitivity analyses. We will consider whether an overall summary is meaningful, and if it is, use random-effects analysis to produce it. We plan to carry out the following subgroup analyses based on:
1. gestation at trial entry: 24 to 28 weeks' gestation; 29 to 34 weeks' gestation; gestation mixed or unknown; 2. whether suspected intrauterine growth restriction at trial entry: suspected intrauterine growth restriction; no suspected intrauterine growth restriction; mixed or unknown. The following primary outcomes will be used in subgroup analysis. We will assess differences between subgroups using interaction tests available within (RevMan 2012).
Sensitivity analysis
In future updates, if more studies are identified and included in analyses, we plan to carry out sensitivity analyses to explore the effect of trial quality assessed by concealment of allocation, high attrition rates, or both, with poor quality studies being excluded from the analyses in order to assess whether this makes any difference to the overall result.
R E S U L T S Description of studies Results of the search
A total of seven trials were identified and four trials met our inclusion criteria (GRIT 2003; Mesbah 2003; Odendaal 1990; Sibai 1994) 
Included studies
Four trials with a total of 425 women are included in this review.
Setting
One trial, was a UK based multi-centre trial involving 69 hospitals in 13 European countries (GRIT 2003) . The other three trials were single-centre trials, based in Egypt (Mesbah 2003), South Africa (Odendaal 1990) , and the USA (Sibai 1994).
Participants
In one trial, (GRIT 2003) , 548 pregnant women with fetal growth restriction between 24 and 36 weeks' gestation, an umbilical artery Doppler waveform recorded and clinical uncertainty whether immediate delivery was indicated were examined. A subset of women from this trial (GRIT 2003) at less than or equal to 34 weeks' gestation (n = 262), who had severe pre-eclampsia were included in this review. Mesbah 2003 included 30 women with severe pre eclampsia between 28 and 33 weeks' gestation; Odendaal 1990 included 38 women with severe pre-eclampsia between 28 and 34 weeks' gestation; and Sibai 1994 included 95 women with severe pre-eclampsia at 28 to 32 weeks' gestation.
Interventions
In all trials, women had a 24-to 48-hour period of stabilisation during which they were given steroids to accelerate fetal lung maturity and if necessary magnesium sulphate to prevent seizures and antihypertensives to lower blood pressure. If they continued to meet the eligibility criteria at the end of this period they were then randomised. They were either randomised to the interventionist group, which involved immediate delivery by caesarean section or induction, or to the expectant management group, who were managed with hospitalisation and intensive maternal and fetal monitoring. Earlier delivery in this expectant group was implemented if either the maternal or fetal condition deteriorated, as determined by prespecified criteria.
Outcomes
The main outcomes in all studies included maternal, perinatal and neonatal morbidity and mortality outcomes. Only one trial included long-term outcomes (GRIT 2003) : measures of longterm growth and development at two years. For further details see Characteristics of included studies.
Excluded studies
Two trials were excluded as they did not meet the inclusion criteria of the review (Gruppo di Studio1998; Langenveld 2011). In both trials, the women did not have severe pre-eclampsia. See table of Characteristics of excluded studies.
Risk of bias in included studies
The four trials were relatively small. Overall, two trials were judged to have a low risk of bias (GRIT 2003; Sibai 1994) , one was unclear (Odendaal 1990) 
Allocation
For one study, the method used for randomisation and concealment of allocation was not described (Odendaal 1990) ; in the other, three trials both methods of randomisation and concealment were adequate (GRIT 2003; Mesbah 2003; Sibai 1994) .
Blinding
Blinding of participants, personnel or outcome assessors was not described in three of the trials (Mesbah 2003; Odendaal 1990; Sibai 1994) . Blinding of outcome assessment for long-term outcomes such as Griffiths assessment was reported in one trial (GRIT 2003) .
Incomplete outcome data
In one trial (Sibai 1994), all women appear to have been accounted for in the results. In one trial individual patient data for a subset of women with severe pre-eclampsia were provided by the authors of the original trial and it is not possible to tell how complete this data set is (GRIT 2003) . In another trial, it is not clear from results tables how many were included in the analyses (Odendaal 1990) . In one trial 41 women were recruited, but 11 (27%) were judged too compromised for expectant management and were delivered by caesarean section and after randomisation, five patients appear to be missing from the results table 2 (Mesbah 2003).
Selective reporting
All expected outcomes appear to have been reported upon in all four trials (GRIT 2003; Mesbah 2003; Odendaal 1990; Sibai 1994) .
Other potential sources of bias
In two studies, baseline characteristics were similar between groups and no other sources of bias were apparent (Odendaal 1990; Sibai 1994) . In one study, other bias may have been introduced as only a subset of the original randomised sample provided data for analysis, but this was not clear (GRIT 2003) . In one study, the severe group were excluded from the study and no baseline characteristics described for this group of patients (Mesbah 2003 
Secondary outcomes
Women allocated to the interventionist group were more likely to have a caesarean section (four trials; 425 women; RR 1.09, 95% CI 1.01 to 1.18), Analysis 1.18, than those allocated an expectant policy. There were no statistically significant differences between the two management strategies for renal failure (two trials; 133 women; RR 0.30, 95% CI 0.01 to 6.97), Analysis 1.7, or placental abruption (two trials; 133 women; RR 0.80, 95% CI 0.26 to 2.40), Analysis 1.9. Liver failure, cardiac arrest and the need for invasive monitoring for the woman were not reported in any of the trials. This review suggests that an interventionist policy of care may be associated with increased morbidity for the baby. For example, those babies whose mothers had been allocated to the interventionist group had more hyaline membrane disease (two trials; 133 women; RR 2.30, 95% CI 1.39 to 3.81), Analysis 1.12, were more likely to require ventilation (two trials; 300 women; RR 1.50, 95% CI 1.11 to 2.02), Analysis 1.14, and were more likely to have a lower gestation at birth (days) (four trials; 425 women; randomeffects analysis; average mean difference (MD) -9.91, 95% CI -16.37 to -3.45; Heterogeneity: Tau² = 31.74; I² = 76%), Analysis 1.19. Also, babies whose mothers had been allocated to the interventionist group were at increased risk of developing necrotising enterocolitis, (three trials; 395 women; RR 2.10, 95% CI 0.93 to 4.79), Analysis 1.13, although the results were not statistically significant, the confidence interval only just overlaps the line of no effect. This effect could be clarified by more data in future updates. Nevertheless, babies allocated to the interventionist policy were less likely to be small-for-gestational age (two trials; 125 women; RR 0.30, 95% CI 0.14 to 0.65), Analysis Other outcomes on use of health service resources were not reported in any of the trials (need for intensive care for the woman; need for high-dependency care or observation, or both, for the woman; surfactant for the baby).
D I S C U S S I O N
Timing the delivery of a very premature infant in the presence of severe pre-eclampsia is a difficult clinical decision. When the mother's life is in danger there is no doubt that delivery is the only correct course of action. This situation is rare. More usually, the risks of maternal morbidity or intrauterine fetal demise, if the pregnancy is continued, have to be constantly balanced against the hazards of prematurity to the fetus if delivered. Most obstetricians would probably be cautious and expedite delivery in favour of the outcome for the mother and being able to guarantee a live baby at delivery. What is not clear is to what level this (if at all), adversely affects the baby.
Only the GRIT study pre-specified fetal assessment parameters as entry criteria into the study. The other studies used fetal assessment to trigger delivery if there was evidence of significant compromise. It is therefore not possible to compare the trials for the condition of the fetuses on trial entry. However it is unlikely that there would have been any clinical differences where this was not formally assessed at trial entry. If there were signs of imminent fetal demise then the women would not have been randomised into the trials. But there is the potential for unseen bias and future trials must include a formal assessment of fetal wellbeing on trial entry.
Currently there are insufficient data to justify any of our prespecified subgroup analyses. These will be included in future updates of this review, when larger trials become available.
It is not possible to draw firm conclusions from this review. However, the evidence is promising that short-term morbidity for the baby may be reduced by a policy of expectant care. This is perhaps surprising given that expectant management increases the length of time a fetus is within the hostile environment, with the potential to adversely affect fetal growth. In fact this is often stated as a reason for intervention. The results of this review suggest otherwise. While the babies in the expectant management group were smaller, their short-term outcomes were better. Before this policy can be recommended in clinical practice, further evidence is required to demonstrate that there is truly a short-term benefit for the baby and that it continues in the longer term. Reassurance is also needed to demonstrate that there is no increase in mortality for the child, or in morbidity for the mother.
Summary of main results
There is insufficient evidence for reliable conclusions about the effects of either management approach on stillbirth or death after delivery. However, there is some evidence from this review to suggest that a policy of delaying delivery reduces the morbidity experienced in the neonatal period of life. Fewer babies had intraventricular haemorrhages, hyaline membrane disease and reduced levels of ventilation in those allocated to expectant management. Babies in this group were also less likely to be admitted to the neonatal intensive care unit and when admitted stayed there for shorter periods of time. There were insufficient data to draw any conclusions about the effect a policy of expectant care had on the mothers health. None of the studies included had sufficient sample size to demonstrate differences in maternal outcome.
Overall completeness and applicability of evidence
There is insufficient evidence from this review to recommend a particular management policy for this area of obstetric care. The numbers of participants in the trials is too small to be able to demonstrate differences in most significant (primary) outcomes and where differences are found there is a considerable level heterogeneity or the contribution is from only one trial. The same is true for the analysis of the secondary outcome measures.
Quality of the evidence
Three of the trials included in the review were judged to be at unclear risk of both performance and detection bias. It is not possible to blind personnel and participants to interventions and most outcomes are objective outcomes, and are unlikely to be affected by blinding e.g. death, eclampsia. One study (Mesbah 2003) , was in addition judged to be at risk of attrition bias. The GRIT 2003 trial was not originally designed to examine severe pre-eclampsia. It looked at interventionist versus expectant management for babies with growth restriction. A by-product of this study, was that a subset of women also had severe pre-eclampsia and it is these women who have been included in the review.
Potential biases in the review process
J Thornton was the Principle Investigator for the GRIT 2003 trial. To remove the potential for bias, the GRIT trial data were supplied directly to two other review authors (D Churchill, L Jones) from the trial statistician. J Thornton had no dealings with the acquisition, preparation or analysis of the GRIT trial data in this review.
A U T H O R S ' C O N C L U S I O N S Implications for practice
These data are insufficient to reach any firm conclusions about the comparative effects of these alternative strategies for the care of women with severe early onset pre-eclampsia. Nevertheless, the apparent increase in some measures of neonatal morbidity associated with interventionist care suggests that early delivery would need to be justified by a realistic expectation of harm to the mother if the pregnancy was continued.
Implications for research
Large trials are needed to confirm whether the benefits for the child associated with a policy of expectant care are real, and to provide reassurance that there is no increase in risk of morbidity or mortality for the mother.
A C K N O W L E D G E M E N T S
As part of the pre-publication editorial process, this review has been commented on by three peers (an editor and two referees who are external to the editorial team) and the Group's Statistical Adviser.
The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane Pregnancy and Childbirth Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, NHS or the Department of Health. 
R E F E R E N C E S
References to studies included in this review
C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
GRIT 2003
Methods Multi-centre randomised controlled trial. Setting: 69 hospitals in 13 European countries. 
Notes
Only a subset of IPD data were included and analysed in this review (women with hypertension plus either proteinuria or IUGR)
Risk of bias
Bias
Authors' judgement Support for judgement
Random sequence generation (selection bias)
Low risk "A paper based number sequence with balanced blocks of 8-12 weeks used except during office hours when a computer-generated sequence was used."
Allocation concealment (selection bias) Low risk "An independent programmer organised allocation, using both randomisation and minimisation." "The process was designed to mask allocation from participating clin-
icians, including those with access to the central trial office."
Blinding of participants and personnel (performance bias) All outcomes
Low risk Not possible to blind -but most of the outcomes not likely to be influenced by lack of blinding Blinding of outcome assessment (detection bias) All outcomes
Low risk Some blinding of outcome assessment for long-term outcomes such as Griffiths assessment: "Assessors were masked to the child's group allocations"
Incomplete outcome data (attrition bias) All outcomes
Unclear risk A subset of IPD data was provided of women with severe PE (n = 262 -hypertension and IUGR and/or proteinuria). It is not possible to tell how complete this data set is, as it was provided by the authors of the original study Selective reporting (reporting bias) Low risk All expected outcomes appear to have been reported upon.
Other bias Unclear risk Unclear. Other bias may have been introduced as only a subset of the original randomised sample has provided data for analysis
Mesbah 2003
Methods Randomisation was generated from a random number sequence table. Blind allocation was made using consecutively sealed envelopes. Odd numbers = aggressive management, even numbers = expectant management. Analysis was by ITT. Follow-up was judged to be 100% Participants 30 pregnant women with severe PE between 28 and 33 + 6 days gestation. Severe PE was defined as a BP > 180/120 mmHg on 2 occasions 30 minutes apart; or a BP between 160 to 180/110 to 120 mmHg on 2 occasions 6 hrs apart. All participants had > 500 mg of proteinuria on a 24 hr urine collection measure. Exclusions were women who needed delivery for either a maternal or fetal condition in the 1st 24 hrs
Interventions
The group assigned to aggressive management were given steroids and then allowed 48 hrs to lapse before either an induction of labour was attempted or CS carried out. Women assigned to expectant management also had steroids but were then managed conservatively with bed rest, observations and nifedipine to control their BP. The indications for delivery in expectant management were, imminent eclampsia, deteriorating renal function, spontaneous preterm labour, absent EDF or a non-reassuring CTG, and reaching 34 weeks Notes 8 women in the interventionist group and 5 in the expectant group deteriorated while in hospital on bed rest and were randomised immediately. The trial recruited from January 1986 to January 1988.
Risk of bias
Bias
Authors' judgement Support for judgement
Unclear risk Not described.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding of participants and personnel (performance bias) All outcomes Unclear risk Not reported.
Blinding of outcome assessment (detection bias) All outcomes Unclear risk Not reported.
Unclear risk 58 women eligible with severe PE; 20 had to be delivered before randomisation because of severe maternal complications or fetal distress.
Odendaal 1990 (Continued)
20 were randomised to the aggressive-management group; 18 were randomised to the expectant group -not clear from results tables how many analysed -but presume no loss to follow-up as not described in the text ITT not stated.
Selective reporting (reporting bias) Low risk All expected outcomes reported upon.
Other bias
Low risk Groups seem similar -including 20 women excluded prior to randomisation (correspondence with author)
Sibai 1994
Methods Randomisation was by computer-generated random number. Concealment of allocation by consecutively-numbered sealed, opaque, envelopes. Analysis -ITT basis. Follow-up -100%
Participants 95 women with severe PE at 28-32 weeks' gestation. Severe PE defined as a persistent elevation of BP >/= 160/110 mmHg, proteinuria > 500 mg in 24 hrs and uric acid > 5 mg/dL. Exclusions: associated medical conditions, renal failure, diabetes or connective tissue disorders, associated obstetric complications, multiple pregnancies and preterm labour Interventions All eligible women in 24 hrs before trial entry: betamethasone 12 mg, repeated after 24 hrs, MgSO4 for 24 hrs. If BP 160/110 mmHg or more, hydralazine or nifedipine depending on clinician preference Interventionist: delivery by either CS or by induction of labour, on the basis of their obstetric condition. Expectant: maternal and fetal monitoring on an antenatal ward. If either the maternal or fetal condition deteriorated or they reached 34 weeks' gestation, delivery using the most appropriate method Outcomes Women: eclampsia, gestation at delivery (mean), CS, placental abruption, HELLP syndrome, renal failure, pulmonary oedema, postpartum length of stay. Baby: birthweight (mean), admission to NICU, length of stay in NICU, SGA, RDS, NEC, bronchopulmonary dysplasia, cerebral haemorrhage Notes The trial recruited from January 1991 to July 1993.
Risk of bias
Bias
Authors' judgement Support for judgement
Low risk "Computer-generated random assignments."
Characteristics of excluded studies [ordered by study ID]
Study
Reason for exclusion Gruppo di Studio1998 Not women with severe pre-eclampsia. This randomised trial compared routine treatment with calcium channel blockers in mild to moderate hypertension
Langenveld 2011 Not women with severe pre-eclampsia. This multi-centre, randomised trial compared induction of labour versus expectant monitoring for gestation hypertension or mild pre-eclampsia
Characteristics of ongoing studies [ordered by study ID]
Duvekot 2011
Trial name or title TOTEM study (temporise or terminate pregnancy in women with severe pre-eclampsia at 28-34 weeks): a study protocol Methods Randomised controlled trial. Multi-centre trial -women admitted in all Dutch tertiary care hospitals Participants Women with severe pre-eclampsia, gestational age at inclusion of 27.6 to 33.5 weeks, singleton pregnancy, estimated fetal weight 500 g and no known major fetal congenital abnormalities Interventions Delivery at least 48 hours after admission (described as "termination of pregnancy") OR expectant management Outcomes Primary outcomes: composite major maternal and neonatal morbidity and mortality Short-term maternal outcome is defined as the occurrence of major complications (pulmonary oedema, encephalopathy/eclampsia, acute respiratory distress syndrome, cerebrovascular incident, abruption placentae, liver haematoma/liver rupture, acute fatty liver of pregnancy, severe renal insufficiency, thromboembolism)
Secondary outcomes: long-term neonatal outcome using Bailey-3 assessment and maternal long-term outcome defined as persistent morbidity 
